Kalytera Therapeutics (TSXV:KALY) announced the development of the multi-center location, as part of its clinical trials to evaluate cannabidiol to treat Graft versus Host Disease.
As quoted in the press release:
Kalytera is developing this clinical trial plan with the intent of obtaining FDA and EMEA approval for commercialization.
Kalytera expects to finalize and publish the details of its clinical trial plan during the current quarter ending June 30, 2017. The plan will include the clinical trial designs, the anticipated timelines for initiation and completion, as well as the principal endpoints. The trials are intended to build on the encouraging data seen in the recently completed Phase 2a Clinical Trial.